Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management
Stem-cell innovator poised to advance the commercialization of its cancer treatment, with
Experienced management team joins company, with more than 80 years of cumulative experience expanding access to innovative treatments for the patients who need them most
To advance the commercialization of Omisirge® (omidubicel-onlv), a NAM-modified cell therapy for allogenic hematopoietic stem cell transplant, Gamida Cell has named industry stalwart Dr.
“Gamida Cell has made great strides in advancing potentially curative cell therapies for cancer and has demonstrated the tremendous potential of its life-saving therapies to improve prospects for patients who cannot find appropriate donors,” said Wiley. “With Highbridge's support, I look forward to leading Gamida Cell into its next phase as we work with hospitals across the
Wiley, Nealon, and Frame collectively bring more than 80 years of experience in building, growing, and commercializing innovative pharmaceutical treatments globally:
-
Dr.
Joe Wiley foundedAmryt Pharma and served as the CEO until it was acquired byChiesi Farmaceutici inApril 2023 . Prior to his role at Amryt, Wiley served as the Principal atSofinnova Ventures and Medical Director at Astellas Pharma, and he held multiple investment management roles following his work as a neurologist. -
Rory Nealon was the co-founder, Chief Financial and Operating Officer atAmryt Pharma from 2015 through its acquisition in 2023. Before joining Amryt, he served executive roles at , first as the Chief Financial Officer then as the Chief Operations Officer.Trinity Biotech -
Sheila Frame most recently served as President Americas ofAmryt Pharma until it’s sale to theChiesi Farmaceutici in 2023. Frame has spent much of her career in executive positions leading the commercialization and growth of several important pharmaceutical products in oncology, immunology, and rare diseases in the US as well as globally.
“Through our recent transaction and infusion of new capital, we are demonstrating our commitment to supporting this mission-driven company as it works toward broadening the availability of its critically important treatment,” said
About Gamida Cell
Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge® (omidubicel-onlv), an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK (natural killer) cell therapy candidate being investigated for the treatment of hematologic malignancies. Gamida Cell operates as a wholly owned subsidiary of
About
Founded in 1992,
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618870004/en/
Media Contact
For Highbridge, please contact
Source: Gamida Cell